Highlights Can-Fite BioPharma Ltd.

Equities

CANF

IL0010944739

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 08:49:49 2024-05-12 am EDT			5-day change	1st Jan Change
2.7 ^ILa	0.00%		-3.57%	+3.85%

May. 12	Transcript : Can-Fite BioPharma Ltd. - Special Call
May. 09	Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	May. 09	CI
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602	May. 06	CI
Can-Fite Biopharma Ltd. Announces Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis, Also Known as Non-Alcoholic Steatohepatitis, for the Company's Ongoing Phase IIb Clinical Study	Apr. 03	CI
Can-Fite Biopharma Ltd. Announces Clinical Update	Mar. 28	CI
Can-Fite BioPharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Can-Fite Biopharma Ltd. to Present Data from the Pancreatic and Liver Cancer Programs	Mar. 11	CI
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the Canadian Intellectual Property Office	Feb. 28	CI
Can-Fite BioPharma Ltd. Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication	Jan. 30	CI
Can-Fite Biopharma Ltd. Announces Results from Randomized Phase 3 Clinical Trial	Jan. 29	CI
Can-Fite BioPharma Ltd. Reports New Data on Namodenoson?s Anti-Obesity Mechanism of Action	Dec. 20	CI
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan	Dec. 18	RE
Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson	Dec. 18	CI
Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients	Dec. 04	CI
Can-Fite BioPharma Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 30	CI
Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson	Nov. 21	CI
Can-Fite Biopharma Ltd. Provides Business Update	Nov. 01	CI
Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal	23-10-30	CI
Can-Fite Biopharma Ltd. Enters into an Agreement with Collaborations Pharmaceuticals Inc to Develop Anti-Cancer Drugs Utilizing Artificial Intelligence	23-10-26	CI
Can-Fite BioPharma Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
Can-Fite Enters Rare Genetic Disease Field Based on Impactful Findings of A Fondazione Telethon and Naples University Researcher Showing Piclidenoson Is Efficacious in Treating Lowe Syndrome	23-08-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Can-Fite BioPharma Ltd.

Equities

CANF

IL0010944739

Highlights

Filters